Cornell Tech campus to name ‘Feeney Way’

There will soon be a second “Feeney Way” at Cornell: a central thoroughfare at Cornell Tech to be named in honor of the transformative impact and legacy of Charles F. “Chuck” Feeney ’56, the university’s most generous donor.

Cornell’s first Fashion Expo takes on New York City

The College of Human Ecology’s first Cornell Fashion Expo, held April 14, gave student designers a chance to present their work to industry experts and Cornell alumni in New York City, one of the fashion capitals of the world.

Cerebral blood vessels reveal potential stroke drug target

Strokes cause changes in gene activity in affected small blood vessels in the brain, changes that may be targetable with existing or future drugs to mitigate brain injury or improve stroke recovery, according to Weill Cornell Medicine scientists.

(Almost) everyone likes a helpful trash robot

In an experiment, most people in a Manhattan plaza welcomed trash barrel robots and happily gave them garbage, though some found them to be creepy.

Edward Meyer ’49, Weill Cornell Medicine benefactor, dies

Edward H. Meyer ’49, a member of Weill Cornell Medicine’s Board of Fellows and devoted benefactor, died April 11 in New York, at age 96.

BioEntrepreneurship Initiative fosters entrepreneurial community

Members of the Cornell entrepreneurial community gathered to celebrate a successful first year of the BioEntrepreneurship Initiative at the program’s culminating workshop on March 18 in Midtown Manhattan.

Around Cornell

Organoids shown to speed glycoengineered vaccine development

Using a biomaterials-based organoid, a multi-institution team led by Matt DeLisa of Cornell Engineering was able to assess the strength of the immune response to a glycoengineered vaccine in days, instead of months.

Four different autism subtypes identified in brain study

People with autism spectrum disorder can be classified into four distinct subtypes based on their brain activity and behavior, according to a study from Weill Cornell Medicine investigators.

Antibody targets omicron and other SARS-CoV-2 variants

A team  has identified an antibody that appears to block infection by all dominant variants of the virus that causes COVID-19, including omicron. Their discovery could lead to more potent vaccines and new antibody-based treatments.